The Advanced Therapies Program is designed as an integrated translational framework to convert cutting-edge discoveries into clinically deployable therapies. It brings together multidisciplinary teams operating within a coordinated pipeline from target discovery to first-in-human clinical evaluation
The program is organized around three complementary pillars:
A central challenge in the field is the fragmentation of translational processes. Engineering, safety, manufacturing, and clinical development often evolve in disconnected workflows, delaying prioritization and increasing late-stage failure. To address this, the program establishes a unified structure integrating modular engineering, safety-by-design, harmonized benchmarking, GMP-aligned development, and early regulatory planning.
The program focuses on next-generation modalities, including cell and gene therapies, immune redirection platforms (CAR-T, CAR-NK, engager-based STAb strategies), and RNA-based approaches, targeting unmet needs in hematological malignancies and solid tumors. By embedding translational criteria early, it enables robust prioritization and accelerates clinical readiness.
Supported by strong clinical integration, GMP capabilities, and strategic partnerships, the program aims to position itself as a reference hub for advanced therapy medicinal products (ATMPs) and to contribute to the advancement of precision medicine.
The traslational clinical research program is constituted by 10 groups:
Director:
Luis Álvarez-Vallina(ELIMINAR)
Tel:
93 316 07 56
Doctor Aiguader, 88
08003 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
